Terms: = Ovarian cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S AND Prognosis
22 results:
1. Overexpression of HER2/her3 and clinical feature of ovarian cancer.
Chung YW; Kim S; Hong JH; Lee JK; Lee NW; Lee YS; Song JY
J Gynecol Oncol; 2019 Sep; 30(5):e75. PubMed ID: 31328457
[TBL] [Abstract] [Full Text] [Related]
2. SWI/SNF-Compromised cancers Are Susceptible to Bromodomain Inhibitors.
Shorstova T; Marques M; Su J; Johnston J; Kleinman CL; Hamel N; Huang S; Alaoui-Jamali MA; Foulkes WD; Witcher M
Cancer Res; 2019 May; 79(10):2761-2774. PubMed ID: 30877105
[TBL] [Abstract] [Full Text] [Related]
3. Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-her3.
Pallerla S; Naik H; Singh S; Gauthier T; Sable R; Jois SD
J Pept Sci; 2018 Feb; 24(2):. PubMed ID: 29436155
[TBL] [Abstract] [Full Text] [Related]
4. ErbB Receptors and cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic impact of her3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract] [Full Text] [Related]
6. Pyrosequencing-Based Assays for Rapid Detection of HER2 and her3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting her3 in Retroperitoneal Leiomyosarcoma.
González-Alonso P; Chamizo C; Moreno V; Madoz-Gúrpide J; Carvajal N; Daoud L; Zazo S; Martín-Aparicio E; Cristóbal I; Rincón R; García-Foncillas J; Rojo F
Int J Mol Sci; 2015 Aug; 16(8):19447-57. PubMed ID: 26287187
[TBL] [Abstract] [Full Text] [Related]
7. Reactive oxygen species regulate ERBB2 and erbb3 expression via miR-199a/125b and DNA methylation.
He J; Xu Q; Jing Y; Agani F; Qian X; Carpenter R; Li Q; Wang XR; Peiper SS; Lu Z; Liu LZ; Jiang BH
EMBO Rep; 2012 Dec; 13(12):1116-22. PubMed ID: 23146892
[TBL] [Abstract] [Full Text] [Related]
8. Association between growth factor heregulin1α and receptors in growth of ovarian cancer cell line with high potentiality of peritoneal dissemination.
Nishiyama H; Soeda S; Watanabe T; Fujimori K
Fukushima J Med Sci; 2012; 58(1):22-32. PubMed ID: 22790889
[TBL] [Abstract] [Full Text] [Related]
9. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors.
Cruz-López O; Conejo-García A; Núñez MC; Kimatrai M; García-Rubiño ME; Morales F; Gómez-Pérez V; Campos JM
Curr Med Chem; 2011; 18(7):943-63. PubMed ID: 21254978
[TBL] [Abstract] [Full Text] [Related]
10. her3 is a determinant for poor prognosis in melanoma.
Reschke M; Mihic-Probst D; van der Horst EH; Knyazev P; Wild PJ; Hutterer M; Meyer S; Dummer R; Moch H; Ullrich A
Clin Cancer Res; 2008 Aug; 14(16):5188-97. PubMed ID: 18698037
[TBL] [Abstract] [Full Text] [Related]
11. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.
Lafky JM; Wilken JA; Baron AT; Maihle NJ
Biochim Biophys Acta; 2008 Apr; 1785(2):232-65. PubMed ID: 18291115
[TBL] [Abstract] [Full Text] [Related]
12. Expression of the epidermal growth factor system in endometrioid endometrial cancer.
Ejskjaer K; Sørensen BS; Poulsen SS; Forman A; Nexø E; Mogensen O
Gynecol Oncol; 2007 Jan; 104(1):158-67. PubMed ID: 16962163
[TBL] [Abstract] [Full Text] [Related]
13. erbb-3 predicts survival in ovarian cancer.
Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
[TBL] [Abstract] [Full Text] [Related]
14. Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
Horak E; Heitner T; Robinson MK; Simmons HH; Garrison J; Russeva M; Furmanova P; Lou J; Zhou Y; Yuan QA; Weiner LM; Adams GP; Marks JD
Cancer Biother Radiopharm; 2005 Dec; 20(6):603-13. PubMed ID: 16398612
[TBL] [Abstract] [Full Text] [Related]
15. [Relationship of expression of C-erbB2, C-erbb3, and C-erbB4 with ovarian carcinoma].
Li L; Zhong YP; Zhang W; Zhang JQ; Yao ZQ
Ai Zheng; 2004 May; 23(5):568-72. PubMed ID: 15142456
[TBL] [Abstract] [Full Text] [Related]
16. Essential roles of Her2/erbB2 in cardiac development and function.
Negro A; Brar BK; Lee KF
Recent Prog Horm Res; 2004; 59():1-12. PubMed ID: 14749494
[TBL] [Abstract] [Full Text] [Related]
17. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract] [Full Text] [Related]
18. Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40.
Furger C; Fiddes RJ; Quinn DI; Bova RJ; Daly RJ; Sutherland RL
Cancer Res; 1998 May; 58(9):1773-8. PubMed ID: 9581810
[TBL] [Abstract] [Full Text] [Related]
19. Overexpression of p53, EGFR, c-erbB2 and c-erbb3 in endometrioid carcinoma of the ovary.
Leng J; Lang J; Shen K; Guo L
Chin Med Sci J; 1997 Jun; 12(2):67-70. PubMed ID: 11324501
[TBL] [Abstract] [Full Text] [Related]
20. [Overexpression of C-erbb3 in transitional cell carcinoma of the ovary].
Shen K; Lang J; Guo L
Zhonghua Fu Chan Ke Za Zhi; 1995 Nov; 30(11):658-61. PubMed ID: 8745489
[TBL] [Abstract] [Full Text] [Related]
[Next]
